The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1270 articles
GLP-1 medications have surged from diabetes treatment to mainstream wellness. This article examines their medical benefits, potential downsides, and the evolving societal perception of weight loss.
The landscape of weight management in India is on the cusp of a significant transformation with the advent of oral GLP-1 therapies. Driven by innovation from Chinese pharmaceutical companies and the impending patent expirations of existing treatments, these new pill-based options promise greater accessibility and affordability, fundamentally reshaping how obesity and metabolic disorders are addressed.
Recent preclinical research suggests that inconsistent use of GLP-1 medications like Ozempic and Wegovy may diminish their effectiveness over time. Discover the science behind adherence and how to optimize your therapy.
The rise of GLP-1 medications has led to an unexpected surge in hot sauce sales. Explore the science behind altered taste perception and how it's influencing consumer choices.
GLP-1 therapies are revolutionizing weight loss, but their widespread adoption raises critical questions about diagnostic preparedness. This article explores the growing need for robust testing frameworks to ensure the safe and effective use of these powerful medications.
The world of weight management has been significantly impacted by the emergence of GLP-1 receptor agonists. These medications, including popular drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), have garnered immense attention for their effectiveness in promoting weight loss and improving metabolic health. But what exactly are these drugs, how do they work, and what should individuals considering them know?
Zealand Pharma and Boehringer Ingelheim announced breakthrough Phase 3 results for survodutide, a dual GLP-1 and glucagon receptor agonist, demonstrating significant weight reduction and metabolic improvements in adults with obesity or overweight.
GLP-1 medications like Ozempic and Wegovy have transformed weight loss. But what exactly happens inside your body? We break down the science, mechanisms, and sustainability of peptide therapy.
Eli Lilly's newly launched oral weight loss medication, Foundayo, has demonstrated significant early traction in the US market, with thousands of prescriptions issued within its first two weeks. This launch marks a pivotal moment in the evolving landscape of weight management therapies, particularly in the context of established injectables like semaglutide (Wegovy).
